Inizio Ignite

A Scapegoat for Site Payment Challenges

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Driving Documentation Integrity Through Structured Drug Data

Establishing a robust framework for regulatory success requires moving beyond fragmented information silos toward a unified, digital-first approach. Comprehensive oversight of the pharmaceutical lifecycle depends on the ability to transform raw information into actionable insights, ensuring that every data point contributes to a larger narrative of safety and efficacy. By prioritizing specialized platforms that aggregate and organize complex information, organizations can achieve a level of transparency that satisfies the most stringent global standards while fostering a culture of continuous improvement.

Contamination Control with Toxicological Reference Data

Centralizing expert-verified toxicological datasets is now a critical requirement for modern pharmaceutical facilities operating under stringent global regulations. By transitioning from generic cleaning limits to precise Health-Based Exposure Limits derived from high-quality platforms, manufacturers ensure that cleaning validation protocols are scientifically sound and audit-ready. This approach integrates rigorous toxicological risk assessment into the broader contamination control strategy, safeguarding patient health while optimizing multi-product manufacturing efficiency and regulatory compliance.

Aligning Global Clinical Trials with Standardized Drug Data

Modern drug development necessitates a shift from fragmented data silos to a unified, intelligence-driven framework. Achieving global regulatory alignment requires a sophisticated approach to trial documentation standards and pharmaceutical regulatory governance, ensuring that clinical trial design remains robust across multiple jurisdictions. By leveraging standardized drug intelligence, sponsors can enhance submission readiness and maintain cross-border compliance, ultimately accelerating the delivery of life-saving therapies to patients worldwide.
- Advertisement -

Managing site payments is not an easy task. They are frustrating, burdensome and a drain of time and resources. CROs, specifically project managers, are often tasked by their sponsor partners to manage the site payment process and consequently are deemed at fault for any issues that arise, such as late or inaccurate payments.

As a result, project managers often spend hours verifying payments and fielding site inquiries on the status of a payment, causing frustration and increased employee turnover. These issues and complexities are only multiplied when dealing with site payments on a global basis as they come with their own set of regulations and standards.

For CROs, outsourcing the entire site payment process to a third party has the potential to introduce additional complexities and risks to the process.Fortunately, technology exists today that can streamline the site payment process, and give CROs the tools they need to more efciently and effectively handle the site payment process – without the headaches.

Historically, the clinical trial industry has been known as being slow to adopt, with the common fear that the implementation of a new solution could interrupt current work flow regardless of how inefficient current processes are. However, solutions today are being strategically built to t CROs’ work ows without interruption and confusing on boarding processes.Listed below are specific ways technology can impact CROs and help produce better clinical trial experiences for all.

Technology Delivers a Better Way to Pay as Trials Expand Globally
Advanced and evolving technology in payment solutions eases the burden on CROs in a number of ways, such as helping to navigate payment complexities as trials expand globally at an increasing rate. According to Clinicaltrials.gov, 47% of current clinical trials are conducted outside of the U.S., which adds another layer of complexity due to additional regulations, languages and currency types. Choosing a technology that is proven to handle global payment regulations can decrease your risk of failing to comply with foreign regulations,and enable your team to be confident in their process while still focusing a majority of their efforts on the research.

Technology Improves the CRO Site Relationship
According to the Society of Clinical Research Sites, 65% of sites have less than three months operating cash. This shortage of cash on hand can threaten the timeline and ow of the study. This puts pressure on CROs to ensure sites are getting paid regularly and on time. Lack of cash flow can also put a strain on a site’s relationship with a CRO and lead to questions,which oftentimes are left unanswered.

By introducing efficiencies, control and visibility into payments, sites and CROs are armed with the data they need to confidently answer tough questions with ease. For example: when will my payment arrive? What is this payment for? Why aren’t we being paid for x, y, and z? Centralized financial transparency and automated reconciliation keeps sites operating at peak performance.

Technology Improves Financial Transparency
Paying sites on time is important to the clinical trial process, but when technology is introduced, CROs can also benefit from insightful analytics, leading to better decision-making.

Technology solutions can also provide long-term predictability and budget management,budgeted costs vs. actual expenditures, accruals management and cash ow predictability. The ability to plan,project, and gain insight into costs from financial data can be extremely benecial for all parties involved. These are simply not available for CROs still using Excel spreadsheets.

A significant investment is at stake to complete a single clinical trial, financial transparency is key for all parties involved. Investing in technology makes it easier to keep track of payments. Failure to adhere to clinical trial rules on compliance and transparency can lead to compliance misconduct and fraud, which can include fines,fees and even jail time, in addition to lost time and resources on the trial itself.

Technology Addresses Increasing Industry Regulations
Aggregated payment reporting for health care providers continues to grow globally, with increasing requirements for consolidation of payment data at the healthcare provider level.Requirements outside the U.S. are continuing to develop,at both the country level and through large influential associations.

These reporting requirements represent another disruption to traditional practices to the clinical operations model. Disparate data sources combined with the manual processes on which many organizations rely to track crucial information make it quite difficult and labor intensive to collect and accurately report aggregate spend data as well as the specific transparency requirements of each country and/or associations.

Technology: A Key Advantage for Sponsors, CROs and Sites
With such high stakes involved in completing a clinical trial, the last thing sponsors CROs and sites should have to worry about are payment issues. At the end of the day, how to advance a new drug or treatment through the process of FDA approval (and beyond) should be where time and resources are focused. Implementing technology to automate the process takes the headaches out of equation all while improving CROs relationships with the sponsors and sites it works with.

 

 

Author: Dave Espenshade

Author Image

In his role as Greenphire’s Vice President of CRO Partnerships, Dave leads the efforts to broaden the use of Greenphire’s solution suite among global CRO partners. Greenphire is currently working with eight of the top 10 global CROs and continues to see an increased demand for both its investigator payment solution, eClinicalGPS,and patient reimbursement solution,ClinCard, within this sector.

Greenphire is the leader in global clinical trial payment solutions. Greenphire’s best-in-class solutions optimize clinical trial performance by simplifying and streamlining payment processes from sponsors and CROs to sites and patients. Greenphire’s ClinCard and eClinicalGPS solutions easily handle any type of trial design and complexity, resulting in more accurate and compliant payments globally for both sites and patients. The choice of industry leaders worldwide, Greenphire provides better performance and better data, resulting in better trials. Learn more at www.Greenphire.com.

Company: Greenphire Inc


The global clinical leader in financial software for clinical trials. Greenphire is the leader in global clinical trial financial process automation. Greenphire’s best-in-class solutions optimize clinical trial performance by streamlining payment and logistical workflows from sponsors and CROs to sites and patients. Greenphire’s ClinCard, eClinicalGPS and ConneX solutions easily handle any type of trial design and complexity, resulting in more accurate and compliant payments and simplified travel globally for both sites and patients. The choice of industry leaders worldwide, Greenphire provides better performance and better data, resulting in better trials. Learn more at www.Greenphire.com.

Send Enquiry for this story

By submitting this form you agree to allow www.worldpharmatoday.com to contact you regarding your enquiry.
See our Privacy Policy to learn more.

Latest stories

Related stories

Driving Documentation Integrity Through Structured Drug Data

Establishing a robust framework for regulatory success requires moving beyond fragmented information silos toward a unified, digital-first approach. Comprehensive oversight of the pharmaceutical lifecycle depends on the ability to transform raw information into actionable insights, ensuring that every data point contributes to a larger narrative of safety and efficacy. By prioritizing specialized platforms that aggregate and organize complex information, organizations can achieve a level of transparency that satisfies the most stringent global standards while fostering a culture of continuous improvement.

Contamination Control with Toxicological Reference Data

Centralizing expert-verified toxicological datasets is now a critical requirement for modern pharmaceutical facilities operating under stringent global regulations. By transitioning from generic cleaning limits to precise Health-Based Exposure Limits derived from high-quality platforms, manufacturers ensure that cleaning validation protocols are scientifically sound and audit-ready. This approach integrates rigorous toxicological risk assessment into the broader contamination control strategy, safeguarding patient health while optimizing multi-product manufacturing efficiency and regulatory compliance.

Aligning Global Clinical Trials with Standardized Drug Data

Modern drug development necessitates a shift from fragmented data silos to a unified, intelligence-driven framework. Achieving global regulatory alignment requires a sophisticated approach to trial documentation standards and pharmaceutical regulatory governance, ensuring that clinical trial design remains robust across multiple jurisdictions. By leveraging standardized drug intelligence, sponsors can enhance submission readiness and maintain cross-border compliance, ultimately accelerating the delivery of life-saving therapies to patients worldwide.

Advancing Quality 4.0 Through Centralized Drug Knowledge 

Implementation of a unified data framework serves as the catalyst for modernizing pharmaceutical production, bridging the gap between legacy processes and intelligent automation. By consolidating disparate data streams into a cohesive repository, organizations achieve unprecedented visibility into critical quality attributes and process parameters. This transformation facilitates proactive risk mitigation and ensures that Good Manufacturing Practices are maintained through high-fidelity insights rather than retrospective analysis, ultimately fostering a culture of continuous improvement and operational excellence.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »